Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography
作者:Tiantian Mou、Huihui Jing、Wenjiang Yang、Wei Fang、Cheng Peng、Feng Guo、Xianzhong Zhang、Yan Pang、Yunchuan Ma
DOI:10.1016/j.bmc.2009.12.022
日期:2010.2
pyridaben, a mitochondrial complex I (MC-I) inhibitor, is well correlated with blood flow. Based on the synthesis and characterization of pyridaben analogue 2-tert-butyl-5-[2-(2-[18F]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([18F]FP2OP), this study assessed its potential to be developed as myocardial perfusion imaging (MPI) agent. Methods: The tosylate labeling precursor 2-(2-(4-(tert-b
线虫复合物I(MC-I)抑制剂哒虫啉的心肌提取与血流密切相关。基于的合成和表征哒类似物2-叔丁基-5- [2-(2- [ 18 F] fluroethoxy)乙氧基]苄氧基] -4-氯-2- ħ -哒嗪-3-酮([ 18 ˚F ] FP2OP),这项研究评估了其作为心肌灌注显像(MPI)试剂的潜力。 方法:甲苯磺酸酯标记前体2-(2-(4-(叔丁基-5-氯-6-氧代-1,6-二氢-哒嗪-4-基氧基甲基)苄氧基)乙氧基)乙基酯(OTs-P2OP)合成了非放射性的2-叔丁基-5- [2-(2- [2- [ 19 F]氟乙氧基)乙氧基]苄氧基] -4-氯-2 H-哒嗪-3-酮([ 19 F] FP2OP),通过IR,1 H NMR,13 C NMR和MS分析进行表征。通过用18 F取代前体OTs-P2OP的甲苯磺酰基,放射性标记的复合物[ 18制备了F] FP2OP,并对其体外理化性质,体内生物